{
  "meta": {
    "title": "57_Pharmacology_Neet_2023",
    "url": "https://brainandscalpel.vercel.app/57-pharmacology-neet-2023-0ecc56e0.html",
    "scrapedAt": "2025-11-30T12:58:09.297Z"
  },
  "questions": [
    {
      "text": "A bronchial asthma patient on inhalational steroids presented with white patchy lesions on the tongue and buccal mucosa. What is the drug that can be used to treat this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Clotrimazole"
        },
        {
          "id": 2,
          "text": "Griseofulvin"
        },
        {
          "id": 3,
          "text": "Terbinafine"
        },
        {
          "id": 4,
          "text": "Flucytosine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The given clinical scenario of&nbsp;white patchy lesions on the tongue and buccal mucosa in a patient using&nbsp;inhalational steroids is&nbsp;<strong>oral candidiasis.</strong> The drug that can be used for the treatment is <strong>clotrimazole</strong>.</p>\n<p><span data-preserver-spaces=\"true\">MDI results in the <strong>deposition</strong> of steroids in the oropharyngeal space, which can cause cough, dysphonia, and oropharyngeal candidiasis.</span></p>\n<div class=\"page\" title=\"Page 854\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Clotrimazole</strong>&nbsp;is a topical <strong>imidazole</strong> used in the treatment of tinea infections like <strong>ringworm</strong>. It is particularly used for the treatment of <strong>vaginitis</strong> as a&nbsp;once-daily application because of its long-lasting residual effect.</p>\n<div class=\"page\" title=\"Page 854\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<div class=\"page\" title=\"Page 854\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>For oral candidiasis, 10 mg troche of clotrimazole is allowed to dissolve in the mouth 3-4 times a day. Alternatively, lotion or gel is applied and swirled in the mouth for as long as possible. Side effects are local irritation and a burning sensation.</p>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n</div>\n<p>&nbsp;</p><p>Other options:</p>\n<p>Option B:&nbsp;<strong>Griseofulvin</strong>&nbsp;acts by&nbsp;<strong>inhibiting microtubule assembly</strong>, disrupting the fungal cell division. It is mainly used against dermatophytes and is the drug of choice for <strong>tinea capitis</strong> in children. It is not effective against <em>Candida</em>.</p>\n<p>Option C:&nbsp;<strong>Terbinafine</strong>&nbsp;acts by&nbsp;<strong>inhibiting</strong>&nbsp;<strong>epoxidation of fungal squalene</strong>&nbsp;that<strong>&nbsp;</strong>reduces&nbsp;ergosterol biosynthesis. It is helpful for treating nail onychomycosis and tinea capitis.</p>\n<p>Option D:&nbsp;<strong>Flucytosine</strong>&nbsp;acts by inhibiting fungal DNA synthesis. It is used exclusively in combination with <strong>amphotericin B</strong> for <strong>cryptococcal meningitis.</strong></p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8169",
      "difficulty": "medium"
    },
    {
      "text": "A pregnant woman with a history of bronchial asthma is in the third stage of labor. Which of the following drugs should be avoided in the management of postpartum hemorrhage in this mother?",
      "choices": [
        {
          "id": 1,
          "text": "Carboprost"
        },
        {
          "id": 2,
          "text": "Oxytocin"
        },
        {
          "id": 3,
          "text": "Dinoprostone"
        },
        {
          "id": 4,
          "text": "Methyl ergometrine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The drug that should be avoided in the management of postpartum hemorrhage in this mother with a history of <strong>bronchial asthma</strong> is <strong>carboprost</strong>.</p>\n<div class=\"page\" title=\"Page 504\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Carboprost is an analog of <strong>PGF2&alpha;</strong>. It is used in obstetrics&nbsp;to induce <strong>second-trimester abortions</strong> and to control <strong>postpartum</strong> <strong>hemorrhage</strong>. Vomiting, diarrhea, and <strong>bronchoconstriction</strong> can occur.</p>\n</div>\n</div>\n</div>\n</div>\n<p>Contraindications of carboprost:</p>\n<table>\n<tbody>\n<tr>\n<td><strong>Absolute&nbsp;</strong></td>\n<td><strong>Relative</strong></td>\n</tr>\n<tr>\n<td>\n<ul>\n<li>Asthma</li>\n<li>Pulmonary hypertension</li>\n<li>Suspected amniotic fluid embolism</li>\n</ul>\n</td>\n<td>\n<ul>\n<li>Pre-eclampsia</li>\n<li>Renal disease</li>\n<li>Liver disease</li>\n<li>Heart disease</li>\n</ul>\n</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div><p>Other options :</p>\n<p>Option B: Oxytocin is the <strong>first-line drug</strong> to prevent and treat PPH according to WHO guidelines. It is administered by intravenous route and may lead to <strong>hypotension</strong> and reflex tachycardia.</p>\n<p>Option C:&nbsp;<strong>Dinoprostone</strong>&nbsp;is a prostaglandin E2 analog used for&nbsp;cervical ripening, induction of labor, and in&nbsp;atony treatment. It should be <strong>avoided</strong> in patients with a history of <strong>asthma</strong>, <strong>glaucoma</strong>, or <strong>myocardial infarction</strong>. One major adverse effect is uterine hyperstimulation.</p>\n<div class=\"page\" title=\"Page 831\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option D: Ergot derivatives are used in the control of <strong>postpartum</strong> uterine bleeding. It is given <strong>intramuscularly</strong> and is effective within 1&ndash;5 minutes. It is given at the time of delivery of the placenta or immediately after if bleeding is significant. Side effects are gastrointestinal disturbances like diarrhea, nausea, and vomiting.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8137",
      "difficulty": "medium"
    },
    {
      "text": "Name the drug that acts on both the marked areas.",
      "choices": [
        {
          "id": 1,
          "text": "Sacubitril"
        },
        {
          "id": 2,
          "text": "Omapatrilat"
        },
        {
          "id": 3,
          "text": "Losartan"
        },
        {
          "id": 4,
          "text": "Nesiritide"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The drug that acts on both the marked areas is <strong>omapatrilat</strong>.</p>\n<p><strong>Omapatrilat</strong>&nbsp;is a<strong>&nbsp;dual inhibitor </strong>of <strong>neutral</strong> <strong>endopeptidase</strong> <strong>and&nbsp;Angiotensin-converting enzyme</strong> (ACE). It decreases angiotensin II and increases atrial and brain natriuretic peptide, promoting <strong>vasodilation</strong>, <strong>diuresis</strong>, <strong>and anti-hypertrophic effect.</strong></p>\n<p>Other options:</p>\n<p>Option A -&nbsp;Sacubitril is a&nbsp;<strong>neprilysin inhibitor.&nbsp;</strong>It reduces the&nbsp;breakdown of natriuretic peptides such as ANP, BNP, and CNP, thereby increasing their levels.&nbsp;Sacubitril combined with valsartan reduces mortality in&nbsp;<strong>heart failure </strong>with<strong> reduced ejection fraction</strong>&nbsp;(HFrEF).</p>\n<p>Option C -&nbsp;<strong>Losartan</strong>&nbsp;is the angiotensin receptor blocker used in the treatment of hypertension.&nbsp;<strong>Hyperkalemia</strong>&nbsp;is an important side effect of ARBs. It&nbsp;<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">appears to be a safe and efficacious agent to&nbsp;<strong>lower serum uric acid</strong>&nbsp;levels in patients with hyperuricemia.</span></span></p>\n<div class=\"ng-scope\">\n<div class=\"ng-scope\">\n<p>Option D -&nbsp;<strong>Nesiritide </strong>is a<strong>&nbsp;recombinant human brain natriuretic peptide </strong>(BNP)<strong>.</strong> It causes vasodilatation and natriuresis. It is administered intravenously and used in <strong>acute decompensated heart failure</strong>.&nbsp;</p>\n</div>\n</div>",
      "question_images": [
        "https://cdn1.dailyrounds.org/uploads/dc86a0c269924557ae4c7be217c65898.JPEG"
      ],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8155",
      "difficulty": "medium"
    },
    {
      "text": "A patient with a previous history of myocardial infarction and ventricular arrhythmia is on treatment for a few months. He developed fatigue, dyspnea, and weight gain. He had also developed pulmonary fibrosis. Which of the following drugs is responsible for the above-mentioned side effects?",
      "choices": [
        {
          "id": 1,
          "text": "Amiodarone"
        },
        {
          "id": 2,
          "text": "Atenolol"
        },
        {
          "id": 3,
          "text": "Aspirin"
        },
        {
          "id": 4,
          "text": "Spironolactone"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The&nbsp;drug that is responsible for the above-mentioned side effects is <strong>amiodarone</strong>.</p>\n<p>Amiodarone is a class III <strong>antiarrhythmic</strong> drug. The most serious<strong> adverse effect</strong> during chronic amiodarone therapy is <strong>pulmonary fibrosis</strong>, which is rapidly progressive and fatal.&nbsp;The side effects of amiodarone include:</p>\n<ul>\n<li>Pulmonary fibrosis</li>\n<li>Hypotension, depressed myocardial function</li>\n<li>Corneal microdeposits</li>\n<li>Hepatotoxicity</li>\n<li>Neuropathies</li>\n<li>Photosensitivity</li>\n<li>Hypo- or hyperthyroidism</li>\n</ul>\n<p>Other options:</p>\n<p>Option B:&nbsp;<strong>Atenolol</strong>&nbsp;is a beta-1 selective antagonist.&nbsp;<strong>Bradycardia</strong>, fatigue, and cold extremities are common adverse effects. It is used in <strong>combination</strong> with a <strong>diuretic</strong>, in <strong>elderly</strong> patients with <strong>isolated</strong> systolic <strong>hypertension</strong>. CNS side effects like depression and nightmares are seen.</p>\n<div class=\"page\" title=\"Page 235\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option C: Aspirin is a nonsteroidal anti-inflammatory drug (<strong>NSAID</strong>)&nbsp;that blocks the formation of <strong>thromboxane</strong> <strong>A<sub>2</sub></strong> by acetylation of COX1. Through this mechanism, it shows&nbsp;antipyretic, analgesic, and anti-inflammatory actions. Higher doses can result in <strong>bleeding</strong>.</p>\n</div>\n</div>\n</div>\n</div>\n<div class=\"page\" title=\"Page 714\">Option D:&nbsp;<strong>Spironolactone</strong>&nbsp;is a potasium-sparing diuretic. It is a&nbsp;<strong>competitive inhibitor</strong>&nbsp;of the&nbsp;<strong>mineralocorticoid receptor</strong>&nbsp;in the&nbsp;<strong>late distal tubule</strong>&nbsp;and<strong>&nbsp;collecting duct</strong>&nbsp;of the kidneys. It&nbsp;promotes sodium diuresis&nbsp;but&nbsp;maintains the body's potassium levels. It is contraindicated in patients with <strong>hyperkalemia</strong>. Side effects are <strong>gynecomastia</strong>, impotence, decreased libido, and menstrual irregularities.</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8136",
      "difficulty": "easy"
    },
    {
      "text": "A young female comes to the emergency department after consuming 100 tablets of aspirin. What should be the next step in management?",
      "choices": [
        {
          "id": 1,
          "text": "N-acetyl cysteine to replenish glutathione stores"
        },
        {
          "id": 2,
          "text": "Pralidoxime"
        },
        {
          "id": 3,
          "text": "Glucagon to control bradycardia and hypoglycemia"
        },
        {
          "id": 4,
          "text": "Give sodium bicarbonate to alkalize urine"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The next step in the management of this patient who consumed 100 tablets of aspirin is to give <strong>sodium</strong> <strong>bicarbonate</strong> to <strong>alkalize</strong> the urine.</p>\n<p>Alkalinization of urine will be helpful in the removal of aspirin, which is a&nbsp;<strong>weakly acidic drug</strong>&nbsp;and is susceptible to<strong>&nbsp;ion trapping</strong> in the&nbsp;urine. It is done by administration of&nbsp;<strong>sodium bicarbonate</strong>&nbsp;in 1 L of 5% dextrose in water (D5W). It is infused intravenously&nbsp;at twice the maintenance fluid requirements.</p>\n<p>Alkalinization of urine is&nbsp;<strong>contraindicated</strong>&nbsp;in&nbsp;<strong>renal failure</strong>&nbsp;or if fluid administration may worsen&nbsp;<strong>pulmonary edema</strong>&nbsp;or congestive heart failure.</p><p>Other options:</p>\n<p>Option A:&nbsp;<strong>N-acetyl cysteine&nbsp;</strong>is used as an antidote for the treatment of&nbsp;<strong>paracetamol</strong>&nbsp;poisoning&nbsp;which&nbsp;<strong>replenishes&nbsp;glutathione</strong> stores in the liver.</p>\n<p>Option B:&nbsp;<strong>Pralidoxime&nbsp;</strong>is also used in organophosphate poisoning. It regenerates active&nbsp;<strong>acetylcholinesterase</strong>&nbsp;and relieves skeletal muscle end-plate block. It is usually used as an&nbsp;<strong>adjuvant</strong>&nbsp;to atropine.</p>\n<p>Option D:&nbsp;<strong>Glucagon</strong>&nbsp;is used in beta-blocker toxicity.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8154",
      "difficulty": "medium"
    },
    {
      "text": "A chronic smoker was on nicotine replacement therapy and clonidine tablets for smoking de-addiction. He stopped taking clonidine tablets and now presents with a headache. What is the reason behind this condition?",
      "choices": [
        {
          "id": 1,
          "text": "Postural hypotension"
        },
        {
          "id": 2,
          "text": "Receptor upregulation"
        },
        {
          "id": 3,
          "text": "Rebound hypertension"
        },
        {
          "id": 4,
          "text": "Receptor hypersensitivity"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The mechanism that causes headache in this patient, who stopped taking clonidine is <strong>rebound hypertension.</strong></p>\n<p>Clonidine is an <strong>alpha-2 receptor agonist</strong> and a centrally acting <strong>antihypertensive</strong> agent. It treats high blood pressure by stimulating <strong>presynaptic α<sub>2</sub> receptors</strong> in the vasomotor center in the brainstem. This binding has a <strong>sympatholytic</strong> <strong>effect</strong>, by <strong>suppressing </strong>the release of <strong>norepinephrine</strong> and other sympathomimetics.</p>\n<p>Abrupt withdrawal after long-term therapy can result in <strong>rebound hypertension, </strong>restlessness, and sympathetic overactivity. <strong>Dry mouth</strong> and <strong>sedation</strong> are the major side effects of clonidine. It can also cause <strong>impotency</strong> and <strong>constipation.</strong></p>\n<div class=\"page\" title=\"Page 171\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p><strong>Phentolamine</strong> is used for the control of hypertension due to clonidine withdrawal.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8138",
      "difficulty": "medium"
    },
    {
      "text": "A patient with recurrent attacks of gout was started on a therapy that inhibits the synthesis of uric acid. His symptoms were reduced after therapy. Which drug was he started on?",
      "choices": [
        {
          "id": 1,
          "text": "Probenecid"
        },
        {
          "id": 2,
          "text": "Colchicine"
        },
        {
          "id": 3,
          "text": "Diclofenac"
        },
        {
          "id": 4,
          "text": "Allopurinol"
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p><strong>Allopurinol </strong>which<strong>&nbsp;inhibits uric acid synthesis</strong>&nbsp;is the likely drug that was added to the regimen<strong>.</strong></p>\n<p>It is a<strong>&nbsp;purine antimetabolite&nbsp;</strong>and a competitive<strong>&nbsp;inhibitor </strong>of the<strong> xanthine oxidase </strong>enzyme. It prevents the conversion of hypoxanthine and xanthine to uric acid <strong>reducing plasma uric acid</strong> levels. The <strong>metabolite </strong>of allopurinol called<strong> oxypurinol</strong> is a <strong>non-competitive inhibitor </strong>of xanthine oxidase.</p>\n<div class=\"page\" title=\"Page 709\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>It is used in the <strong>treatment</strong> of hyperuricemia in patients with <strong>gout</strong> and also in patients with hematological malignancies about to undergo <strong>chemotherapy</strong>.</p>\n</div>\n</div>\n</div>\n</div><p>Other options:</p>\n<p>Option A:&nbsp;<strong>Probenecid</strong>&nbsp;is a&nbsp;<strong>uricosuric agent</strong>&nbsp;that promotes the excretion of uric acids by&nbsp;<strong>inhibiting</strong>&nbsp;the&nbsp;<strong>organic anion transporter,&nbsp;</strong>particularly URAT-1<strong>&nbsp;</strong>in the<strong>&nbsp;renal tubule.&nbsp;</strong>It is used to decrease the body pool of urate in patients with&nbsp;<strong>chronic gout</strong>. It is used as an adjuvant to allopurinol in chronic gout and hyperuricemia. Plenty of fluids are given to&nbsp;<strong>avoid urate calculi</strong>&nbsp;formation.</p>\n<p>Option B:&nbsp;Colchicine is an&nbsp;<strong>antimitotic</strong>&nbsp;drug that is used in the treatment of&nbsp;<strong>acute gout</strong>. It acts by&nbsp;<strong>inhibiting microtubule</strong>&nbsp;and&nbsp;<strong>spindle formation.&nbsp;</strong>Side effects are nausea, vomiting, myelosuppression, aplastic anemia, and rhabdomyolysis.</p>\n<div class=\"page\" title=\"Page 709\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>Option C:&nbsp;<strong>Diclofenac </strong>is a commonly used <strong>NSAID </strong>that has<strong>&nbsp;</strong>analgesic, antipyretic, and anti-inflammatory activities. It acts by inhibiting the&nbsp;<strong>cyclooxygenase-2 </strong>enzyme. Side effects are rashes, fluid retention, edema, and <strong>renal function</strong> impairment.</p>\n</div>\n</div>\n</div>\n</div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8168",
      "difficulty": "easy"
    },
    {
      "text": "A patient with a malignancy is undergoing chemotherapy. The platelet counts were reduced after the previous cycle of chemotherapy. Which of the following drugs can be used in the treatment of this patient?",
      "choices": [
        {
          "id": 1,
          "text": "Oprelvekin (IL-11)"
        },
        {
          "id": 2,
          "text": "Filgrastim"
        },
        {
          "id": 3,
          "text": "Erythropoietin"
        },
        {
          "id": 4,
          "text": "Amifostine"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most probable diagnosis for this patient is <strong>chemotherapy-induced thrombocytopenia</strong>.&nbsp;<strong>Oprelvekin</strong> can be used in the treatment of this patient.</p>\n<p><strong>Oprelvekin </strong>is an <strong>IL-11 analog</strong>&nbsp;used in the treatment of chemotherapy-induced thrombocytopenia. It increases thrombopoiesis. It is used in the treatment of&nbsp;<strong>thrombocytopenia</strong>&nbsp;due to <strong>non-myeloid</strong> <strong>malignancies</strong>. Important adverse effects are&nbsp;fluid retention, tachycardia, palpitation, edema, and shortness of breath.</p>\n<p>Other options:</p>\n<p>Option B:&nbsp;<strong>Filgrastim</strong> is a granulocyte-colony-stimulating factor (G-CSF) that is used for the treatment of <strong>severe neutropenia</strong> after high-dose cancer chemotherapy.</p>\n<p>Option C:&nbsp;<strong>Epoetin alfa</strong>&nbsp;and&nbsp;<strong>darbepoetin alfa</strong>&nbsp;are&nbsp;<strong>recombinant human erythropoietin</strong>. They are used in the treatment of&nbsp;<strong>anemias</strong>&nbsp;associated with surgery, AIDS, cancer chemotherapy, and certain chronic inflammatory conditions.&nbsp;</p>\n<p>Option D:&nbsp;<strong>Amifostine</strong> is used in the reduction of&nbsp;<strong>nephrotoxicity</strong>&nbsp;associated with&nbsp;<strong>cisplatin.</strong></p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/d3eb86a316df4843b4677df07a4425c7x1280x1315.JPEG\" alt=\"Explanation Image\">",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8157",
      "difficulty": "medium"
    },
    {
      "text": "The true statement among the following is _____",
      "choices": [
        {
          "id": 1,
          "text": "The dose of telmisartan should be reduced in renal failure but not in hepatic failure."
        },
        {
          "id": 2,
          "text": "The dose of irbesartan should be reduced in case of mild-moderate hepatic failure and renal failure."
        },
        {
          "id": 3,
          "text": "The dose of candesartan should be reduced in mild-moderate liver failure but not in renal failure."
        },
        {
          "id": 4,
          "text": "Losartan acts as thromboxane A2 antagonist and inhibits platelet aggregation."
        }
      ],
      "correct_choice_id": 4,
      "solution": "<p>The true statement is <strong>losartan</strong> acts as a <strong>thromboxane A<sub>2</sub> antagonist</strong> and inhibits platelet aggregation.</p>\n<p>Losartan is a competitive <strong>angiotensin receptor antagonist</strong>. It binds to the AT<sub>1</sub> receptor with high affinity. It is also a<strong> competitive antagonist</strong> of the <strong>thromboxane A2 receptor</strong> and attenuates platelet aggregation.</p>\n<p><strong>Losartan</strong>&nbsp;is the angiotensin receptor blocker used in the treatment of hypertension.&nbsp;<strong>Hyperkalemia</strong>&nbsp;is an important side effect of ARBs. It&nbsp;<span class=\"ILfuVd\" lang=\"en\"><span class=\"hgKElc\">appears to be a safe and efficacious agent to&nbsp;<strong>lower serum uric acid</strong>&nbsp;levels in patients with hyperuricemia.</span></span></p>\n<p>&nbsp;</p><p>Other options:</p>\n<p>Option A: The clearance of telmisartan is mainly by <strong>biliary secretion</strong>. The clearance is affected by hepatic insufficiency.&nbsp;The dose of telmisartan should be <strong>reduced</strong> in <strong>hepatic failure</strong> but not in renal failure.</p>\n<p>Option B: Irbesartan is metabolized to glucuronide conjugate, and is cleared mainly by <strong>biliary excretion</strong>. The plasma clearance is <strong>unaffected</strong> by either <strong>renal</strong> or <strong>mild-to-moderate hepatic insufficiency</strong>. Hence, the dose need not be reduced in either of the cases.</p>\n<p>Option C: The plasma clearance of candesartan is by<strong> biliary excretion</strong> and <strong>renal elimination</strong>. The clearance is affected by renal insufficiency. Hence, the dose should be <strong>reduced</strong> in case of<strong> renal failure</strong> and <strong>not</strong> in mild-moderate <strong>liver failure</strong>.</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8171",
      "difficulty": "medium"
    },
    {
      "text": "A patient given digoxin started having side effects like nausea and vomiting. The serum concentration of digoxin was 4 mg/dL. The plasma therapeutic range is 1 mg/dL. If the half-life of digoxin is 40 hours, how long one should wait before resuming the treatment?",
      "choices": [
        {
          "id": 1,
          "text": "40 hours"
        },
        {
          "id": 2,
          "text": "80 hours"
        },
        {
          "id": 3,
          "text": "120 hours"
        },
        {
          "id": 4,
          "text": "140-180 hours"
        }
      ],
      "correct_choice_id": 2,
      "solution": "<p>The treatment can be resumed <strong>after 80 hours</strong>.</p>\n<p>The <strong>half-life (T<sub>1/2</sub>)</strong> is the time it takes for the plasma concentration of the drug to be<strong> reduced by 50%</strong>.&nbsp;In the given scenario, the half-life of digoxin is given as 40 hours. The serum concentration of digoxin is given as 4 mg/dL.</p>\n<p><strong>After 40 hours</strong>, the serum concentration of digoxin becomes<strong> 2 mg/dL</strong>&nbsp;(half of the initial concentration), and <strong>after 80 hours,</strong> it will be reduced to <strong>1 mg/dL</strong>. So, to reach a serum concentration of 1 mg/dL (therapeutic range), it will take 80 hours.</p>\n<p>&nbsp;</p>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8160",
      "difficulty": "medium"
    },
    {
      "text": "A patient comes to the casualty with organophosphate poisoning. He was started on atropine infusion and pralidoxime. After 2 hours, the patient had a sudden rise in temperature. What is the likely cause of fever?",
      "choices": [
        {
          "id": 1,
          "text": "Atropine toxicity"
        },
        {
          "id": 2,
          "text": "Side effect of pralidoxime"
        },
        {
          "id": 3,
          "text": "Due to organophosphate poisoning"
        },
        {
          "id": 4,
          "text": "Idiopathic"
        }
      ],
      "correct_choice_id": 1,
      "solution": "<p>The most likely cause of fever in this patient is <strong>atropine toxicity</strong>.</p>\n<p>The&nbsp;clinical scenario is suggestive of&nbsp;<strong>organophosphate</strong> consumption and <strong>atropine&nbsp;</strong>is used for its management. Atropine is a <strong>muscarinic receptor antagonist,</strong> and it&nbsp;<strong>competitively blocks</strong> the acetylcholine at muscarinic receptors.&nbsp;</p>\n<p>Organophosphates are powerful <strong>acetylcholinesterase&nbsp;inhibitors</strong>. It is absorbed by inhalation or through the skin. Mucous membranes and the gastrointestinal tract are also the sites for absorption.&nbsp;</p>\n<p>The predominant initial signs are of <strong>muscarinic</strong> excess which includes:&nbsp;<strong>(DUMBBELSS)</strong></p>\n<ul>\n<li><strong>Diarrhoea</strong></li>\n<li><strong>U</strong>rination</li>\n<li><strong>M</strong>iosis</li>\n<li><strong>B</strong>ronchospasm</li>\n<li><strong>B</strong>radycardia</li>\n<li><strong>E</strong>mesis</li>\n<li><strong>L</strong>acrimation</li>\n<li><strong>S</strong>alivation</li>\n<li><strong>S</strong>weating</li>\n</ul>\n<p><strong>Nicotinic manifestations</strong> include twitching of eyelids, tongue, and facial muscles which then leads to paralysis. <strong>CNS stimulation</strong> results in headache, tremors, ataxia, coma, and death.&nbsp;</p>\n<p>Atropine in larger doses can lead to <strong>atropine toxicity</strong>. The features are depicted in the following image:&nbsp;</p><img src=\"https://dhmbxeygs57ff.cloudfront.net/uploads/f8c7a953045b4866a3ccb2eb3a0996afx1280x2559.JPEG\" alt=\"Explanation Image\"><hr><h3>Related Pearl: Drugs used in Organophosphorus Poisoning</h3><table>\n<tbody>\n<tr>\n<td>\n<p><strong>Symptoms</strong></p>\n</td>\n<td>\n<p><strong>Drug used for treatment</strong></p>\n</td>\n</tr>\n<tr>\n<td>\n<p>Muscarinic symptoms and CNS effects</p>\n</td>\n<td>Atropine</td>\n</tr>\n<tr>\n<td>\n<p>Nicotinic symptoms</p>\n</td>\n<td>Pralidoxime</td>\n</tr>\n<tr>\n<td>\n<p>Nicotinic &gt;muscarinic and CNS effects</p>\n</td>\n<td>Diacetyl monoxime-specific cholinesterase reactivator</td>\n</tr>\n<tr>\n<td>\n<p>Convulsions</p>\n</td>\n<td>IV diazepam</td>\n</tr>\n<tr>\n<td>\n<p>Pulmonary oedema, bronchospasm</p>\n</td>\n<td>Oxygen, atropine, intubation, positive pressure ventilation</td>\n</tr>\n</tbody>\n</table><div class=\"table-expand-wrapper\"><button type=\"button\" class=\"table-expand-btn glass-light\">Expand Table</button></div>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8143",
      "difficulty": "easy"
    },
    {
      "text": "The mechanism of action of tissue plasminogen activator is _____",
      "choices": [
        {
          "id": 1,
          "text": "Inhibit extrinsic pathway"
        },
        {
          "id": 2,
          "text": "Inhibits platelet aggregation"
        },
        {
          "id": 3,
          "text": "Enhance fibrin degradation"
        },
        {
          "id": 4,
          "text": "Inhibit clot formation"
        }
      ],
      "correct_choice_id": 3,
      "solution": "<p>The mechanism of action of the tissue plasminogen activator is to <strong>enhance fibrin degradation.</strong></p>\n<p>Tissue plasminogen activators <strong>activate plasminogen</strong> bound to <strong>fibrin</strong>, and catalyze the conversion of plasminogen to&nbsp;<strong>plasmin,</strong>&nbsp;resulting in increased formation of&nbsp;<strong>plasmin</strong><strong>.</strong> This results in fibrinolysis of formed thrombus (thrombolysis).</p>\n<p>It is indicated in pulmonary embolism with hemodynamic instability,&nbsp;<strong>acute ischemic stroke,</strong> and acute myocardial infarction. Recombinant variants of t-PA like reteplase and tenecteplase have a longer half-life.</p>\n<div class=\"page\" title=\"Page 605\">All thrombolytics can cause bleeding, which may be counteracted by the administration of <strong>antifibrinolytics,</strong> such as <strong>aminocaproic acid</strong> and <strong>tranexamic acid.</strong></div>\n<div class=\"page\" title=\"Page 605\">\n<div class=\"section\">\n<div class=\"layoutArea\">\n<div class=\"column\">\n<p>&nbsp;</p>\n</div>\n</div>\n</div>\n</div><hr><h3>Related Pearl: Plasminogen activators (classification of fibrinolytics)</h3><p><strong>Fibrin non-specific</strong> plasminogen activators</p>\n<ul>\n<li>Streptokinase - least fibrin specific and has the lowest incidence of intracranial hemorrhage</li>\n<li>Anistreplase</li>\n<li>Urokinase</li>\n</ul>\n<p><strong>Fibrin specific</strong> plasminogen activators</p>\n<ul>\n<li>Alteplase - has the shortest half-life</li>\n<li>Tenecteplase - most fibrin specific and given as a single bolus dose</li>\n<li>Reteplase</li>\n</ul><hr><h3>Related Pearl: Indications and Contraindications of thrombolysis in Ischemic Stroke</h3><p><strong>Indications for thrombolysis in stroke</strong>&nbsp;</p>\n<ul>\n<li>Clinical diagnosis of stroke</li>\n<li>Onset of symptoms to time of drug administration &lt;3 hours/<strong>4.5</strong> hours</li>\n<li>Age &ge; 18 years</li>\n<li>CT scan showing no haemorrhage or edema of &gt;1/3<sup>rd</sup> of the MCA territory&nbsp;</li>\n</ul>\n<p><strong>Contraindications of thrombolysis in stroke&nbsp;</strong></p>\n<ul>\n<li>Sustained BP &gt;185/110 mmHg despite treatment</li>\n<li>Bleeding diathesis</li>\n<li>Recent head injury or Intracerebral hemorrhage</li>\n<li>Major surgery in preceding 14 days</li>\n<li>Minor stroke symptoms</li>\n<li>Gastrointestinal bleeding in preceding 21 days</li>\n<li>Recent myocardial infarction</li>\n</ul>",
      "question_images": [],
      "explanation_images": [],
      "explanation_video": null,
      "question_id": "MF8170",
      "difficulty": "medium"
    }
  ]
}